Subtypes


Web

  • https://en.wikipedia.org/wiki/Imatinib
  • As a result, these cells stop growing, and even die by a process of cell death (apoptosis).[2] Because the BCR-Abl tyrosine kinase enzyme exists only in cancer cells and not in healthy cells, imatinib works as a form of targeted therapy...
  • http://www.wikidoc.org/index.php/Imatinib
  • WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling.
  • http://www.drugbank.ca/drugs/DB00619
  • Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer.
  • http://www.nps.org.au/medicines/cancers/other-anticancer-medicine...
  • Glivec Tablets is a brand of medicine containing the active ingredient imatinib.
  • http://www.diagnosia.com/en/drug/glivec-100-mg-hard-capsules
  • Glivec is a medicine containing an active substance called imatinib.
  • http://www.drugs.com/uk/imatinib-regiomedica-100-mg-film-coated-t...
  • 3. How to take Imatinib
  • http://www.cancer.gov/about-cancer/treatment/drugs/imatinibmesylate/
  • This page contains brief information about imatinib mesylate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
  • http://www.gistsupport.org/treatments-for-gist/gleevec/imatinib-g...
  • This page answers the following common questions about Gleevec (click the question to skip to that section).
  • http://www.uwhealth.org/health/topic/multum/gleevec/d04758a1.html
  • Imatinib is used to treat certain types of leukemia (blood cancer), bone marrow disorders, and skin cancer, or certain tumors of the stomach and digestive system.
  • http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Tre...
  • Imatinib (Glivec
  • 1 2 3 4 5 6 7 8 9

    News

    Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34+ cells via pre-B-cell leukemia homeobox 1
    Nature - Friday, September 6, 2019
    Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy
    Nature - Friday, September 6, 2019
    Gleevec (imatinib) Gleevec (imatinib) is a brand-name prescription medication. It's used to treat certain types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). It's also used to treat certain types of ski
    Medical News Today - Saturday, August 31, 2019
    Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
    Nature - Monday, March 25, 2019
    HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia
    Nature - Tuesday, December 18, 2018
    Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031
    Doi - Thursday, November 29, 2018
    Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
    Doi - Sunday, November 11, 2018
    Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or Imatinib
    Doi - Friday, May 18, 2018
    Cost Savings Limited With Generic Imatinib
    Physicians Briefing - Wednesday, May 9, 2018
    Generic drugs don't always push prices down 9 hours ago ago There's been only a small drop in the price of imatinib since a generic version was introduced to compete with Gleevec, a new study finds.
    United Press International - Tuesday, May 8, 2018
    Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
    Doi - Thursday, March 29, 2018
    Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
    Nature - Wednesday, February 21, 2018
    Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML
    Nature - Wednesday, January 10, 2018
    A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response
    Nature - Monday, December 11, 2017
    Gleevec (imatinib mesylate) Tablets, for Oral Use
    RXList - Monday, October 30, 2017
    OUTCOME OF FRONTLINE TREATMENT WITH "GENERIC" IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY
    MJHID - Tuesday, October 24, 2017
    OUTCOME OF FRONTLINE TREATMENT WITH "GENERIC" IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY.
    Mjhid - Monday, October 23, 2017
    Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL
    Doi - Tuesday, October 10, 2017
    MORE NEWS

    Videos

    Overview of Gleevec the Brand Name Form of Imatinib
         
    http://www.rxwiki.com/imatinib https://www.youtube.com/watch?v=8q6iXxqUhQ4&list=PLXxn_pCvHVm7XKp6U5_K1B88bqvrJRjIg Gleevec, the brand name form of imatinib, is a prescription medication used to treat different types of cancers of the blood and certa...

    Dr Giuseppe Saglio Compares Efficacy, Safety of Nilotinib with Imatinib for CML Patients
         
    Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib’s side effects are too much for patients, according to a study from Novartis presented at the 56th Annual Meeting of the A...

    Nilotinib Versus Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive CML-CP
         
    At the American Society of Hematology (ASH) 2011, Giuseppe (Beppe) Saglio, MD, Professor of Internal Medicine and Hematology, and Director of the Department of Molecular Medicine and Targeted Therapy at the San Luigi Hospital, University of Turin, Italy, ...

    Gleevecs mechanism of Action
         
    The animation begins by introducing the Philadelphia Chromosome, the result of a reciprocal translocation between chromosomes 9 and 22. More specifically the breakpoint cluster region (BCR) of chromosome 22 is fused with part of the Abelson (ABL) gene on...

    Research Summaries ; Cancer.Net
         
  • In a new study on gastrointestinal stromal tumor (GIST), researchers found that the drug sorafenib (Nexavar) is an effective treatment when imatinib (Gleevec) and/or sunitinib (Sutent) no longer work.

  • 1 2 3 4 5 6 7 8 9

    Images

    Mechanism of action of imatinib
    250px Imatinib 2DACS svg
    Crystallographic structure of tyrosine-protein kinase ABL (rainbow colored, N-terminus = blue, C-terminus = red) complexed with imatinib (spheres, carbon = white, oxygen = red, nitrogen = blue).[37]
    220px Glivec 400mg
    bcr-abl kinase (green), which causes CML, inhibited by imatinib (red; small molecule).
    Mechanism of action of imatinib
    en.wikipedia.org
    250px Imatinib 2DACS svg
    en.wikipedia.org
    Crystallographic structure of tyrosine-protein kinase ABL (rainbow colored, N-terminus = blue, C-terminus = red) complexed with imatinib (spheres, carbon = white, oxygen = red, nitrogen = blue).[37]
    en.wikipedia.org
    220px Glivec 400mg
    en.wikipedia.org
    bcr-abl kinase (green), which causes CML, inhibited by imatinib (red; small molecule).
    en.wikipedia.org
    510px Imatinib in its binding site svg
    Imatinib chemical structure.PNG
    200px Imatinib svg
    Mechanism imatinib
    120px Mechanism imatinib svg
    510px Imatinib in its binding site svg
    en.wikipedia.org
    Imatinib chemical structure.PNG
    en.wikipedia.org
    200px Imatinib svg
    en.wikipedia.org
    Mechanism imatinib
    en.wikipedia.org
    120px Mechanism imatinib svg
    en.wikipedia.org
    File:Imatinib in its binding site.svg
    120px Imatinib in its binding site svg
    Gleevec 400 mg
    Gleevec pills forweb
    Image of Gleevec 400 mg
    File:Imatinib in its binding site.svg
    en.wikipedia.org
    120px Imatinib in its binding site svg
    en.wikipedia.org
    Gleevec 400 mg
    drugs.com
    Gleevec pills forweb
    gistsupport.org
    Image of Gleevec 400 mg
    uwhealth.org
    Image of Gleevec 100 mg
    Thanks to NCI support, Gleevec offers new hope to patients with CML.
    Mechanism of Action of Imatinib
    Imatinib inhibits these kinases by binding to the active site on the kinase molecule.
    GIST Support International posed some questions about skin-related side effects of imatinib and sunitinib to Mario E. Lacouture, MD.
    Image of Gleevec 100 mg
    uwhealth.org
    Thanks to NCI support, Gleevec offers new hope to patients with CML.
    cancer.gov
    Mechanism of Action of Imatinib
    sarcomahelp.org
    Imatinib inhibits these kinases by binding to the active site on the kinase molecule.
    sarcomahelp.org
    GIST Support International posed some questions about skin-related side effects of imatinib and sunitinib to Mario E. Lacouture, MD.
    gistsupport.org
    The US Food and Drug Administration (FDA) has granted imatinib full approval as an adjuvant treatment following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST) in adult patients.
    TUESDAY Oct. 19, 2010 -- A small group of people with chronic myeloid leukemia (CML) who decided to stop taking the cancer drug Gleevec (imatinib) have remained cancer-free two years later, French researchers report.
    Masitinib and imatinib for gastrointestinal stromal tumours trial diagram
    TUESDAY Sept. 21, 2010 -- Continuous treatment with imatinib (Gleevec) is recommended for patients with advanced gastrointestinal cancer, a new study suggests.
    imatinib 328
    The US Food and Drug Administration (FDA) has granted imatinib full approval as an adjuvant treatment following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST) in adult patients.
    obgyn.net
    TUESDAY Oct. 19, 2010 -- A small group of people with chronic myeloid leukemia (CML) who decided to stop taking the cancer drug Gleevec (imatinib) have remained cancer-free two years later, French researchers report.
    drugs.com
    Masitinib and imatinib for gastrointestinal stromal tumours trial diagram
    cancerresearchuk.org
    TUESDAY Sept. 21, 2010 -- Continuous treatment with imatinib (Gleevec) is recommended for patients with advanced gastrointestinal cancer, a new study suggests.
    drugs.com
    imatinib 328
    obgyn.net
    Additional small series of patients who underwent surgery while their metastatic GIST tumors were responding to tyrosine kinase inhibitors (TKIs) imatinib or sunitinib have reported similar results.
    Gleevec 400 mg 400 SL SL Front
    TUESDAY March 22, 2011 -- The death rate of patients with chronic myeloid leukemia who took Gleevec and were in remission two years after treatment was similar to the death rate in the general population, a new study shows.
    THURSDAY March 19, 2009 -- Taking Gleevec after surgery to remove a gastrointestinal stromal tumor improves tumor-free survival, a U.S. study has confirmed.
    Doctor M. Pantaleo focused on Imatinib adjuvant therapy and open issues: which patients should be treated, dose and duration.
    Additional small series of patients who underwent surgery while their metastatic GIST tumors were responding to tyrosine kinase inhibitors (TKIs) imatinib or sunitinib have reported similar results.
    gistsupport.org
    Gleevec 400 mg 400 SL SL Front
    drugs.com
    TUESDAY March 22, 2011 -- The death rate of patients with chronic myeloid leukemia who took Gleevec and were in remission two years after treatment was similar to the death rate in the general population, a new study shows.
    drugs.com
    THURSDAY March 19, 2009 -- Taking Gleevec after surgery to remove a gastrointestinal stromal tumor improves tumor-free survival, a U.S. study has confirmed.
    drugs.com
    Doctor M. Pantaleo focused on Imatinib adjuvant therapy and open issues: which patients should be treated, dose and duration.
    gistsupport.org
    Dr. Morelli (Manager of Laboratory Medicine at INT, Milan) talked about the starting of the first Lab testing the clinical significance of imatinib plasma levels - an observational study in INT evaluating correlations between SNPs, Imatinib plasma levels
    Dr. A. Gronchi (surgeon at INT, Milan) reported on a new European, Australian and New Zealand trial (EORTC62063) evaluating Surgery of Residual Disease in Patients With Metastatic Gastro-intestinal Stromal Tumor Responding to Imatinib Mesylate
    TUESDAY Nov. 18, 2008 -- Gleevec, a wonder drug that effectively treats leukemia and other cancers, may also reverse type 1 diabetes, University of California San Francisco, researchers report.
    When imatinib was first approved in 2001 to treat chronic myeloid leukemia (CML), the full value of the medicine had not been completely realized.
    Cover of Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable and/or Metastatic Gastrointestinal Stromal Tumours that have Progressed on Treatment at a Dose of 400 Mg/Day: A Systematic Review and Econ
    Dr. Morelli (Manager of Laboratory Medicine at INT, Milan) talked about the starting of the first Lab testing the clinical significance of imatinib plasma levels - an observational study in INT evaluating correlations between SNPs, Imatinib plasma levels
    gistsupport.org
    Dr. A. Gronchi (surgeon at INT, Milan) reported on a new European, Australian and New Zealand trial (EORTC62063) evaluating Surgery of Residual Disease in Patients With Metastatic Gastro-intestinal Stromal Tumor Responding to Imatinib Mesylate
    gistsupport.org
    TUESDAY Nov. 18, 2008 -- Gleevec, a wonder drug that effectively treats leukemia and other cancers, may also reverse type 1 diabetes, University of California San Francisco, researchers report.
    drugs.com
    When imatinib was first approved in 2001 to treat chronic myeloid leukemia (CML), the full value of the medicine had not been completely realized.
    innovation.org
    Cover of Clinical Effectiveness and Cost-Effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable and/or Metastatic Gastrointestinal Stromal Tumours that have Progressed on Treatment at a Dose of 400 Mg/Day: A Systematic Review and Econ
    ncbi.nlm.nih.gov
    Gleevec, a promising new type of cancer drug created by Novartis, has been approved by the FDA in record-breaking time.
    (June 16, 2010 - Insidermedicine) A new drug with a similar but more potent mechanism of action as imatinib, commonly known as Gleevec, appears to be more effective for the treatment of chronic myeloid leukemia, according to research published in the New
    But, a small number of patients did not respond or could not tolerate imatinib.
    Imatinib, the first tyrosine kinase inhibitor (TKI), revolutionized the treatment paradigm for patients, nearly tripling the odds of survival, by targeting cancer at the cellular level.
    The day started at 7.30 am with breakfast and registration, and then Dr. Trent gave a thorough introduction to GIST, followed by a description of all the drugs from first line imatinib (Gleevec) to the off-label 3rd and 4th line drugs.
    Gleevec, a promising new type of cancer drug created by Novartis, has been approved by the FDA in record-breaking time.
    drgreene.com
    (June 16, 2010 - Insidermedicine) A new drug with a similar but more potent mechanism of action as imatinib, commonly known as Gleevec, appears to be more effective for the treatment of chronic myeloid leukemia, according to research published in the New
    insidermedicine.com
    But, a small number of patients did not respond or could not tolerate imatinib.
    innovation.org
    Imatinib, the first tyrosine kinase inhibitor (TKI), revolutionized the treatment paradigm for patients, nearly tripling the odds of survival, by targeting cancer at the cellular level.
    innovation.org
    The day started at 7.30 am with breakfast and registration, and then Dr. Trent gave a thorough introduction to GIST, followed by a description of all the drugs from first line imatinib (Gleevec) to the off-label 3rd and 4th line drugs.
    gistsupport.org

    MORE IMAGES